Article Text

Download PDFPDF

Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma
  1. Rachel L Sabado1,
  2. Anna Pavlick2,
  3. Sacha Gnjatic1,3,
  4. Crystal Cruz2,
  5. Isabelita Vengco2,
  6. Farah Hasan1,
  7. Farbod Darvishian2,
  8. Luis Chiriboga2,
  9. Rose Marie Holman1,
  10. Juliet Escalon2,
  11. Caroline Muren2,
  12. Crystal Escano2,
  13. Ethel Yepes2,
  14. Dunbar Sharpe2,
  15. Sylvia Adams2,
  16. Patrick Ott2,
  17. Achim Jungbluth3,
  18. Linda Pan3,
  19. Ralph Venhaus3 and
  20. Nina Bhardwaj1,2
  1. Aff1 grid.137628.90000000121698901New York University School of Medicine New York NY USA
  2. Aff2 grid.137628.90000000419368753Mount Sinai Icahn School of Medicine New York NY USA
  3. Aff3 grid.1052.60000000097371625Ludwig Institute for Cancer Research New York NY USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


The TLR 7/8 agonist, Resiquimod has been shown to induce local activation of immune cells, production of cytokines, and antigen-presentation by dendritic cells, features desirable for cancer vaccine adjuvants. In this study, we evaluated the safety and immunogenicity of vaccination with NY-ESO-1 protein emulsified in Montanide ISA-51 VG when given with or without Resiquimod in surgically resected stage IIB-IV melanoma patients.

Experimental design

This is a two-part study design. Part I represents an open-label dose-escalation with Resiquimod using 2 cohorts treated with 100μg NY-ESO-1 protein emulsified in 1.25mL Montanide (day1) followed by topical application of 1000mg of the 0.2% Resiquimod gel on days 1 and 3 for cohort-1 (N=3) or days 1, 3, and 5 for cohort-2 (N=3). The cycles were repeated every 3 weeks, total of 4 cycles. For part II of the study, patients were blindly randomized to receive 100μg NY-ESO-1 protein emulsified in 1.25mL Montanide (day1) followed by topical application of placebo gel (Arm-A; N=8) or 1000mg of 0.2% Resiquimod gel (Arm-B; N=12) using the dosing regimen established in Part I. Blood samples were collected at baseline, one week after each cycle of vaccination, and at follow-up visit for the assessment of NY-ESO-1-specific humoral and cellular immune responses.


The vaccines were generally well-tolerated, with no grade 4 adverse events or study-related deaths. Most study participants experienced mild adverse reactions reported as Grade 1 or 2 per CTCAE criteria v. 4. One patient experienced a grade 3 syncopal episode that was unrelated to the study drugs and another patient had a grade 3 injection site necrosis that was possibly related to the study drugs. NY-ESO-1 specific antibody responses were induced in both study arms although higher mean antibody titers were observed in Arm B. NY-ESO-1 specific CD4+ T cell responses were induced in patients in both study arms. However, significant NY-ESO-1 CD8+ T cell responses were detected only in Arm B.


The current study shows that Resiquimod is safe and contributes to the induction of immune responses in patients.